The headline loss improvement is largely a non-cash impairment comparison — operating cash burn was essentially flat YoY at ~$11.5M. The U.S. launch delay to 2029 pushes the royalty revenue inflection point further out, but the LATAM 2027 target and cash runway into late Q1 2027 provide a clearer near-term catalyst path. Monitor for definitive commercialization agreements with LATAM partners and scale-up orders from the Sustainable Ingredients program in H2 2026.
Price Chart
Executive Summary
Cibus reported Q1 2026 revenue of $1.68M (up 63% YoY from $1.03M) and a net loss of $21.2M ($-0.33/share), compared to a $49.4M loss ($-1.34/share) in Q1 2025 which included a $21.0M goodwill impairment. The company ended the quarter with $30.3M cash, raised ~$37.3M in net equity proceeds from two offerings in early 2026, and reiterated its target of reducing annual net cash usage to ~$30M or less. While the loss narrowed significantly on an operating basis (excluding the prior-year impairment), the company remains pre-revenue on its core trait licensing model, with the U.S. Rice launch pushed back to 2029.
Key Financial Metrics
Key Facts
- Revenue of $1.68M in Q1 2026, up 63% from $1.03M in Q1 2025, driven by increased program activity and payments.
- Net loss of $21.2M ($-0.33/share) vs $49.4M ($-1.34/share) in Q1 2025; prior year included a $21.0M non-cash goodwill impairment.
- Cash and cash equivalents of $30.3M as of March 31, 2026, up from $9.9M at year-end 2025, after ~$37.3M in net equity proceeds from two public offerings.
- Cash runway extended to late Q1 2027; company on track for annual net cash usage of ~$30M or less in 2026.
- U.S. Rice launch target pushed from 2028 to 2029 due to herbicide registration delays with partner Albaugh; LATAM launch remains on track for 2027.
- Gene-edited traits transferred to Interoc's rice seeds in May 2026, advancing toward LATAM commercialization.
- Sustainable Ingredients program expanded R&D activities under amended contract; targeting scale-up orders in H2 2026.
- Board appointed Thomas Urban in April 2026, adding agribusiness and M&A expertise.
Financial Impact
Revenue up 63% YoY to $1.68M; net loss improved by $28.2M YoY primarily due to absence of $21.0M goodwill impairment and cost reductions; cash position strengthened to $30.3M.
Risk Factors
- U.S. Rice launch delayed to 2029 due to herbicide registration timeline with Albaugh.
- Still pre-revenue on core trait licensing; dependent on partner milestones and regulatory approvals.
- Royalty liability continues to accrue ($244M at March 31, 2026), creating significant long-term debt-like obligation.
- Cash runway only into late Q1 2027; additional financing likely needed before reaching commercial revenue.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-035105 |
| Document: cbus-20260514.htm | 0001628280-26-035105 |
| Document: 0001628280-26-035105-index-headers.html | 0001628280-26-035105 |
| Document: 0001628280-26-035105-index.html | 0001628280-26-035105 |
| Document: 0001628280-26-035105.txt | 0001628280-26-035105 |
| 8-K Data (Synthetic) | 0001628280-26-035105 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 28, 2026 28d ago | Press Release | $1.55 | awaiting T+20 | — | $1.39 (−10.00%) |
Jun 11, 2026 19w ago | Institutional Cluster | $1.25 $1.90 | ▲ +52.00% | ▲ +50.11% | $1.39 (+11.60%) |
Jun 9, 2026 19w ago | 8-K | $1.23 $1.50 | ▲ +21.95% | ▲ +20.50% | $1.39 (+13.41%) |
Jun 8, 2026 20w ago | Press Release | $1.23 $1.50 | ▲ +21.95% | ▲ +20.50% | $1.39 (+13.41%) |
May 26, 2026 21w ago | EFFECT | $1.43 $1.38 | ▲ +3.50% | ▲ +1.55% | $1.39 (+2.45%) |
May 14, 2026 23w ago | 8-K | $1.31 $1.27 | ▼ −3.05% | ▼ −5.17% | $1.39 (+6.49%) |
May 4, 2026 25w ago | Press Release | $1.49 $1.47 | ▼ −1.34% | ▼ −6.99% | $1.39 (−6.38%) |
Apr 20, 2026 27w ago | DEFA14A | $1.49 $1.28 | ▼ −14.09% | ▼ −19.01% | $1.39 (−6.38%) |
Mar 26, 2026 30w ago | 424B5 | $1.88 $1.49 | ▲ +20.74% | ▲ +33.49% | $1.39 (+25.80%) |
Mar 26, 2026 30w ago | Press Release | $2.13 $1.50 | ▼ −29.58% | ▼ −40.24% | $1.39 (−34.51%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers